1) Volante M, Birocco N, Gatti G, et al. Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Hum Pathol. 2014;45:665-73.
2) Lepage C, Ciccolallo L, De-Angelis R, et al. European disparities in malignant digestive endocrine tumors survival. Int J Cancer. 2010;126:2928-2934.
3) Kang H, OConnell JB, Leonardi MJ. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22:183-189.
4) Sorbye H, Strosberg J, Baudin E,et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120:2814-23.
5) Dasari A, Mehta K, Byers LA,et al. et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer 2018;124:807-815.
6) Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172–185
7)Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015 J Natl Compr Canc Netw. 2015;13:78-108.
8) Sorbye H, Welin S, Langer S.W, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma
(WHO G3): The NORDIC NEC study. Ann Oncol. 2013;24:152-160.
9) Yamaguchi T, Machida N, Morizane C, et al.
Multicenter retrospective analysis of systemic chemotherapy foradvanced neuroendocrine carcinoma of the digestive system. Cancer Science. 2014;105:1176-1181.
10) Bajetta E, Catena L, Procopio G,et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59:637-42.
11) Hentic O, Hammel P, Couvelard A,et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr. Relat. Cancer. 2012;19:751-757.
12) Nio K, Arita S, Isobe T,et al. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemother Pharmacol. 2015 ;75:829-35.
13) Ando T, Hosokawa A, Yoshita H, et al. Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma. Gastroenterol Res Pract. 2015;2015:425876.
14) Araki T, Takashima A, Hamaguchi T, et al. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract. Anticancer Drugs. 2016;27:794-9.
15) Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;117:4617-22.
16) Olsen IH, Sorensen JB, Federspiel B, et al. Temozolomide as second or third line treatment of patients with neuroendocrine carcinoma. Scientific World Journal 2012; 2012: 170496.
17) Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15: 338-345; 2009
18) Ekeblad S, Sunddia A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986-75.
19) Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patuents with metastatic pancreatic endocrine carcinoma. Cancer. 2011;117:268-75.
20) Saif MW, Kaley K, Brennan M, et al. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP. 2013;14:498-501.
21) Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018; 36, (suppl; abstr 4004)
22) Owen DH, Alexander AJ, Konda B, et al. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget. 2017;8:104046-104056.
23) Apostolidis L, Bergmann F, Jäger D, et al. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Medicine. 2016; 5:2261–2267.
24) Campana D, Walter T, Pusceddu S, et al. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine. 2018;60:490-498.
25) De Divitiis C, von Arx C, Grimaldi AM, et al. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. J Transl Med. 2016;14:113.
26) Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23:759-67.